Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumors. Eligible patients were adults with progressive, advanced, well-differen...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
